Logo

lung adenocarcinoma

In New TRACERx Data, Personalis MRD Test Shows Improved Sensitivity With Potential Clinical Impact
Premium

The data, some of the first available for the firm's NeXT Personal test, indicated that its higher analytical sensitivity could lead to better risk prediction than competing tests.

Tempus, Lilly Ink Partnership to Offer No-Cost NGS for Advanced NSCLC Patients

Lilly will cover the cost of Tempus' broad-based sequencing tests for advanced non-small cell lung cancer patients to improve biomarker testing access.

Blood Lipid Mass Spectrometry Assay May Enable Early-Stage Lung Cancer Detection

Researchers in China have come up with a machine learning- and lipidomics-based strategy for detecting lung cancer early in blood samples.

Lung Cancer Organizations to Study Epidemiologic, Genomic Causes in Young Patients

The Epidemiology of Young Lung Cancer study will build on a prior genomics study to better characterize NSCLC patients diagnosed before age 40.

Onconova to Enroll Patients With KRAS-Mutated Lung Cancer in Phase I/II Rigosertib Trials

The company will study its investigational drug rigosertib in combination with Opdivo in patients with KRAS-mutated lung cancer.